Halozyme Therapeutics, Inc. vs Eli Lilly & Co.
HALO vs LLY — side-by-side comparison from reported financials. HALO leads 4, LLY leads 6 of 10 comparable metrics.
Halozyme Therapeutics, Inc.
HALO · Healthcare
$111.35+1.38%Mixed
Eli Lilly & Co.
LLY · Healthcare
$1 177.20+0.65%Solid
| Metric | HALO | LLY |
|---|---|---|
| Price | $111.35 | $1 177.20 |
| Market cap | $12.6B | $1.05T |
| Revenue (TTM) | $1.66B | $79.7B |
| Revenue growth | +28.4% | +31.7% |
| Net margin | 24.9% | 33.5% |
| Free cash flow | $806M | $18.2B |
| Net cash (debt) | ($2.01B) | ($35.2B) |
| 1-year price return | +71.0% | +37.6% |
| P/E | 30.3 | 41.6 |
| P/E vs own history (cheap-side %) | 8% | 88% |
| Dividend yield | — | 0.52% |
| Return on equity | 181% | 93% |
| Altman Z-score | — | 7.10 |
| CV checks passed | 9 of 10 | 11 of 10 |
| Employees | 423 | 50,000 |
Full résumé-style profiles: HALO CV · LLY CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.